FDA Accepts Supplement Application for YERVOY (ipilimumab)
The FDA has accepted a supplemental application for YERVOY, an immune checkpoint inhibitor.
Asset / Drug
Drug and asset intelligence for YERVOY with 4 indexed intelligence signals across regulatory, clinical, competitive, and market developments.
Immune Checkpoint Inhibitor
No catalysts indexed for this entity yet.
No related entities indexed yet.
Newsletter
Concise strategic intelligence on regulatory, clinical, competitive, and market developments — free to subscribe.
No paywall. No spam. Unsubscribe anytime.